Summary
Cimetidine, an H2 histamine receptor antagonist, is a potent immunomodulating agent, which acts by inhibiting suppressor T lymphocyte function. The present work investigated the effect, if any, of cimetidine on interleukin-2 (IL-2)-induced natural killer (NK) and lymphokine-activated killer (LAK) cell activities, and on in vivo antitumor activity using syngeneic colon 26 adenocarcinoma as the model. Mimicking the clinical conditions, all in vitro experiments were evaluated with the splenocytes prepared from tumor-bearing BALB/c mice. Ten days after subcutaneous inoculation of tumor cells (5 × 105), animals were treated intraperitoneally daily with phosphate-buffered saline (PBS), cimetidine (2 mg kg−1 day−1), IL-2 (300 000 IU/day), or cimetidine plus IL-2 for 7 consecutive days. The treatment of IL-2 plus cimetidine increased NK and LAK cell activities significantly and synergistically at the end of the treatment (i.e. on day 18) as well as 1 week after the treatment (i.e. on day 25), in comparison with those of the control groups (PBS, cimetidine alone, IL-2 alone). Also, in vivo antitumor activity, as analyzed by a Kaplan-Meier life table with the log-rank test, revealed a significantly prolonged survival in the group treated with IL-2 plus cimetidine compared to the control groups. Phenotyping performed on the murine splenocytes on day 18 indicated a significant reduction in Lyt2-positive cells in the cimetidine-treated group in comparison with the PBS group. A significant increase in asialo GM1-positive cells and IL-2-receptor-positive cells was detected in the group treated with IL-2 plus cimetidine in comparison with the PBS and IL-2 control groups. Therefore, this study indicates a synergistic enhancement of IL-2-induced NK and LAK cell activities in tumor-bearing hosts by cimetidine, a noncytotoxic inhibitor of suppressor T function, and a significantly prolonged survival of tumor-bearing animals treated by IL-2 plus cimetidine. It also suggests the clinical potential of combination therapy of IL-2 with cimetidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brockmeyer NH, Kreutzfelder E, Bluhm CH, Shen G, Kuwert EK, Ohnhaus EE (1985) Stimulating potency of cimetidine on the immune system in man. Br J Clin Pharmacol 21: 567P
Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effect of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810
Chao TY, Chu TM (1989) Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma. Cancer Immunol Immunother 30: 158
Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46: 2784
Flodgren P, Sjogren HO (1985) Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immunol Immunother 19: 28
Flodgren P, Bergstrom S, Jonsson PE, Lindstrom C, Sjogren HO (1983) Metastatic malignant melanoma: regression induced by combined treatment with interferon (HuIFN-α) (Le) and cimetidine. Int J Cancer 32: 657
Gifford RRM, Ferguson RM, Voss BV (1981) Cimetidine reduction of tumor formation in mice. Lancet I: 638
Griswold DE, Alessi S, Badger AM, Poste G, Hanna N (1986) Differential sensitivity of T suppressor cell expression to inhibition by histamine type 2 receptor antagonists. J Immunol 137: 1811
Griswold DP, Corbett TH (1975) A colon tumor model for anticancer agent evaluation. Cancer 36: 2441
Jin Z, Kumar A, Cleveland RP, Murray DL, Kaufman DB (1986) Inhibition of suppressor cell function by cimetidine in a murine model. Clin Immunol Immunopathol 38: 350
Khan MM, Marr-Leisy D, Verlander MS, Bristow MR, Strober S, Goodman M, Melmon KL (1986) The effects of derivatives of histamine on natural suppressor cells. J Immunol 137: 308
McIntosh J, Mule JJ, Merino MJ, Rosenberg SA (1988) Synergistic antitumor effect of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res 48: 4011
Mule JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA (1987) Identification of cellular mechanism operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139: 285
Ogden BE, Hill HR (1980) Histamine regulates lymphocyte mitogenic responses through activation of specific H1 and H2 histamine receptors. Immunol 41: 107
Ohnishi H, Lin KM, Chu TM (1990) Prolongation of serum half-life of interleukin-2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res 50: 1107
Osband ME, Hamilton D, Shen YJ, Cohen E, Schlesinger M, Lavin P, Brown A, McCaffrey R (1981) Successful tumor immunotherapy with cimetidine in mice. Lancet I: 636
Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA (1988) Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48: 122
Ratner S, Heppner GH (1988) Motility and tumoricidal activity of interleukin-2 stimulated lymphocytes. Cancer Res 48: 3374
Rocklin RE, Breard J, Gupta G, Good RA, Melmon KL (1980) Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF). Cell Immunol 51: 226
Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169
Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA (1984) Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946
Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC (1987) Inhibition of suppressor T lymphocytes (Ts) by cimetidine. J Immunol 138: 2760
Wang MC, Lu SD, Mark DF (1984) Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of cysteine residues. Science 222: 257
Wang SR, Zweiman B (1978) Histamine suppression of human lymphocyte responses to mitogens. Cell Immunol 36: 28
Yang JC, Mule JJ, Rosenberg SA (1986) Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J Immunol 137: 715
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakajima, I., Chu, T.M. Synergistic antitumor activity of interleukin-2 and cimetidine against syngeneic murine tumor. Cancer Immunol Immunother 33, 9–14 (1991). https://doi.org/10.1007/BF01742521
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01742521